| 摘要 |
PURPOSE: To obtain a prolactin secretion inhibitor that contains D-6-n-propyl-8β- hydroxymercaptomethylergoline as an effective ingredient together with inactive carriers, and excels in therapy of postpartum hyperlactation, galactorrhea, etc. CONSTITUTION: This prolactin secretion inhibitor contains a new compound, D-6-n-propyl-8β-hydroxymercaptomethylergoline, or its pharmacologically permissible acid addition salt as an effective ingredient together with inactive carriers. This prolactin secretion inhibitor is administered preferably by oral dosage in a dose of 0.01-0.5mg per kg of body weight in the form of a fitting-type gelatin capsule in which the effective ingredient is sealed as a mixture with a standard pharmacological excipient. The above-mentioned effective ingredient compound is synthesized, for example, by a reaction of a compound of formula I (Q is an eliminating group; X is H, Cl or Br; R<2> is H, ethyl, etc.) with a compound of formula II (Y is O, S, etc.).
|
